Diferencia entre revisiones de «Irritable bowel syndrome»
Sin resumen de edición |
(Prepared the page for translation) |
||
| Línea 1: | Línea 1: | ||
<languages/> | |||
<translate> | |||
==Background== | ==Background== | ||
#psychosocial factors | #psychosocial factors | ||
#altered gut motility | #altered gut motility | ||
#hypersensitive intestinal pain perception | #hypersensitive intestinal pain perception | ||
==Evaluation== | ==Evaluation== | ||
===Criteria=== | ===Criteria=== | ||
#Three months of [[abdominal pain]]: | |||
#Three months of [[Special:MyLanguage/abdominal pain|abdominal pain]]: | |||
##relieved by defecation | ##relieved by defecation | ||
##associated with change of stool freq | ##associated with change of stool freq | ||
| Línea 16: | Línea 24: | ||
##passage of mucous | ##passage of mucous | ||
##bloating | ##bloating | ||
==Workup== | ==Workup== | ||
*Diagnosis of exclusion | *Diagnosis of exclusion | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
*[[Post-infectious irritable bowel syndrome]] | |||
*See [[abdominal pain]] | *[[Special:MyLanguage/Post-infectious irritable bowel syndrome|Post-infectious irritable bowel syndrome]] | ||
*See [[Special:MyLanguage/abdominal pain|abdominal pain]] | |||
==Management== | ==Management== | ||
*Consider prescribing [[ondansetron]] up to 24 mg/d for IBS-D<ref>Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617-1625.</ref> | |||
*Consider prescribing [[Special:MyLanguage/ondansetron|ondansetron]] up to 24 mg/d for IBS-D<ref>Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617-1625.</ref> | |||
*Typical bowel regimen treatments for IBS-C | *Typical bowel regimen treatments for IBS-C | ||
**May consider low-dose [[TCA]] if appropriate follow up with PCP will occur | **May consider low-dose [[Special:MyLanguage/TCA|TCA]] if appropriate follow up with PCP will occur | ||
==See Also== | ==See Also== | ||
*[[Abdominal Pain]] | |||
*[[Postinfectious irritable bowel syndrome]] | *[[Special:MyLanguage/Abdominal Pain|Abdominal Pain]] | ||
*[[Special:MyLanguage/Postinfectious irritable bowel syndrome|Postinfectious irritable bowel syndrome]] | |||
==External Links== | ==External Links== | ||
===Patient Information=== | ===Patient Information=== | ||
[http://digestive.niddk.nih.gov/ddiseases/pubs/ibs/ibs_508.pdf Irritable Bowel Syndrome] (National Digestive Diseases Information Clearinghouse) | [http://digestive.niddk.nih.gov/ddiseases/pubs/ibs/ibs_508.pdf Irritable Bowel Syndrome] (National Digestive Diseases Information Clearinghouse) | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:GI]] | [[Category:GI]] | ||
</translate> | |||
Revisión actual - 23:14 4 ene 2026
Background
- psychosocial factors
- altered gut motility
- hypersensitive intestinal pain perception
Evaluation
Criteria
- Three months of abdominal pain:
- relieved by defecation
- associated with change of stool freq
- related to a change in stool consistency
- AND, 2 or more of the following symptoms 25% of the time
- >3 bm per day or < 3 bm per week
- altered stool form
- altered stool passage
- passage of mucous
- bloating
Workup
- Diagnosis of exclusion
Differential Diagnosis
Management
- Consider prescribing ondansetron up to 24 mg/d for IBS-D[1]
- Typical bowel regimen treatments for IBS-C
- May consider low-dose TCA if appropriate follow up with PCP will occur
See Also
External Links
Patient Information
Irritable Bowel Syndrome (National Digestive Diseases Information Clearinghouse)
References
- ↑ Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617-1625.